Stock·NYSE·Healthcare
Becton, Dickinson and Company (BDX)
- Market cap
- $52.78B
- P/E
- 45.06
- Dividend yield
- 2.07%
- Street target
- $195.00median of 15 analysts
- 52-week range
- $127.59 $195.72
The short version
Where BDX stands today, in four lines, and what CleaRank Financial AI makes of it.
BDX at a glance
Becton, Dickinson and Company (BDX): Hold, 55/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($183.89 and $164.10).
- Earnings BDX beat estimates in 8 of its last 8 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $3.6M and bought $1.0M over the last 18 months.
- Valuation P/E of 45.1 against 31.9 for the Healthcare sector: a premium to peers (+41%).
Figures as of October 16, 2026.
CleaRank Financial AI
Becton, Dickinson and Company (BDX) is currently trading at $192.29, just below its median Wall Street price target of $195.00, indicating limited immediate upside according to analysts.
The company operates within the Healthcare sector, specifically in Medical Instruments & Supplies, an industry facing moderate growth expectations. Technically, the stock shows bullish momentum, trading above its 50-day and 200-day moving averages ($183.89 and $164.10), and its 14-day RSI is at 64.87, signaling strength without being overbought. However, insider activity reveals a net seller position, with total sales of $3.6 million against $1 million in purchases, suggesting a degree of caution from management.
Only on CleaRank
Figures we compute ourselves from BDX's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $192.29 is 4.6% above the 50-day simple moving average of $183.89.Price above its 200-day average ›
The price is 17.2% above the 200-day simple moving average of $164.10.50-day average above the 200-day ›
The 50-day average ($183.89) is 12.1% above the 200-day average ($164.10), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 95% of its 52-week range, between $127.59 and $195.72.
BDX share price
Pick a period: each tab shows how far BDX has moved over it, to the last close.
Today's trading
Where BDX sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 45.06 is 41.3% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 2.35 is 31.0% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $1.6B on revenue of $22.5B, a net margin of 7.3%.Beat estimates in most recent reports ›
BDX beat the EPS estimate in 8 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 2.07%, or $3.98 a share a year.
Key statistics
The headline figures for BDX.
As of October 16, 2026, BDX trades at $192.29, with a market value of $52.78B, a P/E ratio of 45.06 and a dividend yield of 2.07%.
What the numbers say
CleaRank Financial AI's reading of BDX's valuation, growth and risks.
Becton, Dickinson and Company (BDX) exhibits a Price-to-Earnings ratio of 45.06, which is considerably higher than the sector median P/E of 31.9, suggesting the stock may be trading at a premium relative to its peers.
The company's fundamentals show a Return on Equity of 6.61% and a Profit Margin of 4.19%, both below the sector medians of 7.3% and not directly comparable to sector averages for Debt-to-Equity. While the company's revenue growth of 5.4% is below the sector average of 8.1%, its operating margin of 15.73% is strong. The current valuation appears stretched when compared to sector averages.
BDX against the Healthcare sector
How BDX compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: BDX trades at a significant premium to sector peers (+41%), suggesting market expectations for superior growth or market position.
Return vs XLV: Since May 5, 2025, BDX has gained 47.6% against a gain of 28.3% for XLV.
Performance against XLV
BDX and the Healthcare sector fund over the same days.
Revenue and earnings
How much BDX sells, and how much of it becomes profit.
Revenue growth: Revenue grew 8.2% in FY2025 to $21.8B, from $20.2B a year earlier.
Profit margin: The net margin was 7.7% in FY2025, down from 8.4% the year before.
Profitable: BDX earned $1.7B in FY2025.
Earnings reality check
Did BDX beat what analysts expected, and how did the stock react?
Earnings record: BDX beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 4 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 6, 2026after close | $3.14 | $3.23 | +2.87% | -0.12% | +2.77% |
| May 7, 2026after close | $2.77 | $2.90 | +4.69% | -2.50% | -5.74% |
| Feb 9, 2026after close | $2.81 | $2.91 | +3.56% | +5.30% | +8.79% |
| Nov 6, 2025after close | $3.91 | $3.96 | +1.28% | +0.25% | +8.82% |
| Aug 7, 2025after close | $3.40 | $3.68 | +8.24% | +3.10% | +3.90% |
| May 1, 2025after close | $3.28 | $3.35 | +2.13% | -0.45% | -0.94% |
| Feb 5, 2025after close | $2.99 | $3.43 | +14.72% | -7.28% | -7.84% |
| Nov 7, 2024after close | $3.77 | $3.81 | +1.06% | +1.99% | +0.03% |
As of October 16, 2026, BDX has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on August 6, 2026, came in 2.87% above the estimate and the stock moved -0.12% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 64.9, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 64.9 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of BDX
The score, the reasoning behind it, and what could move the price next.
Becton, Dickinson and Company (BDX) is trading above its 50-day SMA of $183.89 and its 200-day SMA of $164.10, indicating a generally positive trend.
The 14-day RSI is at 64.87, reflecting bullish momentum without reaching overbought territory, and the MACD is positive at 2.49. The stock is also trading above its 20-day EMA of $184.95. Key support levels are indicated by the moving averages, with the 50-day SMA at $183.89 and the 200-day SMA at $164.10. The current price of $192.29 suggests these averages are acting as support.
Consistent Earnings Beat History ›
Becton, Dickinson and Company (BDX) has a track record of beating EPS estimates in its last four reported quarters, demonstrating operational efficiency and effective execution.
Source: Earnings ReportsProjected Near-Term Revenue Slowdown ›
Wall Street revenue estimates show a projected year-over-year decline of 13.00% for the next quarter, followed by modest growth of 2.00% for the next year, potentially capping near-term upside.
Source: Wall Street Estimates
Moderate Insider Selling Continues ›
Insiders have sold $3.6 million worth of stock against $1 million in purchases, indicating a net seller position. This trend suggests a lack of strong conviction from management at current price levels.
Source: Insider Transactions
- Consider the premium valuation of BDX relative to its sector peers, as its P/E ratio of 45.06 is substantially higher than the sector median of 31.9.
Technical indicators
Momentum and trend for BDX, from its daily closes.
As of October 16, 2026, with BDX at $192.29, its 14-day RSI is 64.9 (showing bullish momentum without being overbought), its 50-day simple moving average is $183.89 and its 200-day is $164.10.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What BDX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, BDX's 1-year correlation of daily returns is +0.25 with S&P 500 (SPY), +0.11 with Nasdaq 100 (QQQ), +0.02 with Bitcoin (BTC) and +0.09 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
7 of 15 analysts rate it a buy or strong buy, 7 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $195.00 is 1.4% above the price.More buy ratings than three months ago ›
7 of 15 rate it a buy now, against 7 of 14 three months ago.
BDX Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Initiates | Underweight |
| Aug 31, 2026 | B of A Securities | Maintains | Neutral |
| Aug 13, 2026 | RBC Capital | Maintains | Sector Perform |
| Aug 7, 2026 | Citigroup | Maintains | Buy |
| Aug 7, 2026 | RBC Capital | Maintains | Sector Perform |
| Aug 7, 2026 | Piper Sandler | Maintains | Neutral |
As of October 16, 2026, 15 Wall Street analysts cover BDX: 7 rate it a buy or strong buy, 7 a hold and 1 a sell or strong sell. Their 12-month price targets range from $165.00 to $225.00, with a median of $195.00, 1.4% above the price of $192.29.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
BDX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from BDX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much BDX tends to move, against the market and on its own.
The long record
BDX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.53% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 38.6%, from August 2023 to May 2025; the price is still 6.4% below that peak.Most 1-year holds ended higher ›
61% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $17,888, against $42,525 in the S&P 500 (SPY).
BDX Drawdowns & Recovery
As of October 16, 2026, BDX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -38.6% (August 2023 to May 2025); it is still 6.4% below that peak, and 61% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into BDX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: BDX trailed the S&P 500 over this period: $17,888 against $42,525.
A $10,000 investment in BDX in October 2016 would be worth about $17,888 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to BDX, and which have not.
Strongest month, January: an average of +5.61%, up in 8 of 10 years.
Weakest month, May: an average of -3.99%, up in 3 of 10 years.
This month, October: has averaged -0.89%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, BDX's strongest calendar month has been January (average +5.61%, up in 8 of 10 years) and its weakest May (average -3.99%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in BDX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BDX today could grow to about $16,611 by 2036 in the base case, with a 90th-percentile outcome near $44,199 and a 10th-percentile outcome around $6,243. The simulation models price only; at today's 2.07% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
BDX Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $236 for BDX by 2030 in the base case, from $192 today (1.2x over 4 years). The 10th-percentile path ends near $127. These are outcomes of a Monte Carlo simulation run on BDX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $148 | $202 | $276 | |
| 2028 | $137 | $213 | $330 | |
| 2029 | $131 | $224 | $383 | |
| 2030 | $127 | $236 | $437 | |
| 2031 | $124 | $248 | $495 |
Method: a lognormal simulation of BDX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
BDX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $1.0M on the open market and sold $3.6M.
As of October 16, 2026, BDX insiders reported 27 open-market sales worth $3.6M and 1 open-market purchase worth $1.0M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 28, 2026 | Michael Feld
Officer
|
Sell | 76 | $14.0K |
| Aug 26, 2026 | Michael Feld
Officer
|
Sell | 165 | $31.1K |
| Aug 13, 2026 | Thomas E Polen Jr
Chief Executive Officer
|
Sell | 4.2K | $768.1K |
| Aug 13, 2026 | Thomas E Polen Jr
Chief Executive Officer
|
Option | 43.3K | $7.2M |
| Aug 11, 2026 | Roland Goette
Officer
|
Sell | 2.4K | $440.9K |
| Jul 27, 2026 | Michael Feld
Officer
|
Sell | 75 | $11.8K |
| Jul 1, 2026 | Bilal Muhsin
Officer
|
Grant | 14.3K | - |
| Jun 26, 2026 | Michael Feld
Officer
|
Sell | 75 | $11.5K |
| Jun 24, 2026 | Michael David Garrison
Officer
|
Sell | 1.1K | $160.2K |
| Jun 10, 2026 | Michael David Garrison
Officer
|
Sell | 1.1K | $166.6K |
| Jun 1, 2026 | Thomas E Polen Jr
Chief Executive Officer
|
Sell | 2.8K | $404.5K |
| Jun 1, 2026 | Peter Menziuso
Officer
|
Grant | 14.3K | - |
| Jun 1, 2026 | Thomas E Polen Jr
Chief Executive Officer
|
Option | 20.2K | $2.5M |
| May 26, 2026 | Michael Feld
Officer
|
Sell | 75 | $11.1K |
| May 7, 2026 | Vitor Roque
Chief Financial Officer
|
Grant | 1.7K | - |
| Apr 27, 2026 | Michael Feld
Officer
|
Sell | 74 | $11.2K |
| Mar 26, 2026 | Michael Feld
Officer
|
Sell | 75 | $11.8K |
| Mar 16, 2026 | Lanesha Minnix
General Counsel
|
Grant | 7.5K | - |
| Mar 2, 2026 | Vitor Roque
Chief Financial Officer
|
Grant | 931 | - |
| Mar 2, 2026 | Pamela L Spikner
Officer
|
Grant | 931 | - |
| Feb 26, 2026 | Michael Feld
Officer
|
Sell | 75 | $13.6K |
| Feb 18, 2026 | Bertram Lee Scott
Director
|
Sell | 953 | $174.0K |
| Jan 27, 2026 | William M. Brown
Director
|
Grant | 1.1K | - |
| Jan 27, 2026 | Carrie L Byington
Director
|
Grant | 1.1K | - |
| Jan 27, 2026 | Robert Andrew Eckert
Director
|
Grant | 1.1K | - |
| Jan 27, 2026 | Gregory J Hayes
Director
|
Grant | 1.1K | - |
| Jan 27, 2026 | Jeffrey William Henderson
Director
|
Grant | 1.1K | - |
| Jan 27, 2026 | Robert Luther Huffines
Director
|
Grant | 1.1K | - |
| Jan 27, 2026 | Christopher Ian Montague Jones
Director
|
Grant | 1.1K | - |
| Jan 27, 2026 | Timothy M Ring
Director
|
Grant | 1.1K | - |
| Jan 27, 2026 | Bertram Lee Scott
Director
|
Grant | 1.1K | - |
| Jan 27, 2026 | Joanne Waldstreicher
Director
|
Grant | 1.1K | - |
| Jan 27, 2026 | Jacqueline Wright
Director
|
Grant | 1.1K | - |
| Jan 26, 2026 | Michael Feld
Officer
|
Sell | 75 | $15.2K |
| Jan 15, 2026 | Michael David Garrison
Officer
|
Sell | 1.6K | $334.0K |
| Jan 15, 2026 | Michael David Garrison
Officer
|
Option | 3.1K | $512.8K |
| Dec 26, 2025 | Michael Feld
Officer
|
Sell | 74 | $14.5K |
| Dec 17, 2025 | Michael David Garrison
Officer
|
Sell | 629 | $123.3K |
| Dec 1, 2025 | Michael Feld
Officer
|
Sell | 75 | $14.5K |
| Dec 1, 2025 | Robert Luther Huffines
Director
|
Grant | 180 | - |
| Dec 1, 2025 | Jacqueline Wright
Director
|
Grant | 180 | - |
| Nov 26, 2025 | Richard Byrd
Officer
|
Grant | 8.8K | - |
| Nov 26, 2025 | Christopher Delorefice
Chief Financial Officer
|
Grant | 6.0K | - |
| Nov 26, 2025 | Michael Feld
Officer
|
Grant | 8.8K | - |
| Nov 26, 2025 | Michael David Garrison
Officer
|
Grant | 10.6K | - |
| Nov 26, 2025 | Roland Goette
Officer
|
Grant | 3.1K | - |
| Nov 26, 2025 | Pavan Kumar Mocherla
Officer
|
Grant | 2.9K | - |
| Nov 26, 2025 | Bilal Muhsin
Officer
|
Grant | 9.5K | - |
| Nov 26, 2025 | Shana Carol Neal
Officer
|
Grant | 10.3K | - |
| Nov 26, 2025 | Thomas E Polen Jr
Chief Executive Officer
|
Grant | 22.5K | - |
| Nov 26, 2025 | David Shan
Officer
|
Grant | 4.5K | - |
| Nov 26, 2025 | Pamela L Spikner
Officer
|
Grant | 1.2K | - |
| Nov 7, 2025 | Bertram Lee Scott
Director
|
Sell | 217 | $38.3K |
| Oct 27, 2025 | Michael Feld
Officer
|
Sell | 57 | $10.6K |
| Sep 26, 2025 | Michael Feld
Officer
|
Sell | 58 | $10.5K |
| Sep 10, 2025 | Claire Fraser
Director
|
Sell | 917 | $171.9K |
| Aug 22, 2025 | Michael Feld
Officer
|
Sell | 57 | $11.3K |
| Aug 11, 2025 | Gregory J Hayes
Director
|
Buy | 5.3K | $1.0M |
| Aug 8, 2025 | Claire Fraser
Director
|
Sell | 863 | $166.0K |
| Jul 18, 2025 | Michael David Garrison
Officer
|
Sell | 1.2K | $213.6K |
| Jul 18, 2025 | Michael David Garrison
Officer
|
Option | 6.4K | $939.2K |
| Jul 2, 2025 | Bilal Muhsin
Officer
|
Grant | 12.2K | - |
| Jun 2, 2025 | David Shan
Officer
|
Sell | 1.2K | $199.6K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.